Navigation Links
Enova Medical Launches Exos Corporation

New company offers innovative casting, splinting and bracing technology

ST. PAUL, Minn., Aug. 31 /PRNewswire/ -- Enova Medical Technologies, Inc. of St. Paul, Minn., and Product Innovations, Inc. (P.I.) of Aspen, Colo., are pleased to announce the launch of Exos Corporation, a joint venture company that will develop and commercialize innovative orthopedic support devices.

Exos will focus on the product development and commercialization surrounding its revolutionary, patentpending technology called OrthoFoam(TM) Dry-Heat Thermoformable Splint/Cast/Brace Systems. Taking a composite materials approach to the construction and custom fitting of orthopedic devices, OrthoFoam technology is expected to radically change the practices surrounding external orthopedic casting, splinting and bracing.

"There is considerable market opportunity for this technology, ranging from emergency room splinting to long-term bracing during patient rehabilitation. Our immediate focus is to manufacture and launch our initial OrthoFoam products for upper extremity injuries," said Fariborz Boor Boor, Enova CEO and Exos President/CEO. "Over the next year, we will release additional products for lower extremity injuries and longer-term bracing needs through a variety of clinical venues."

Roger Heegaard, Enova president/COO and Exos board member, explained that Exos delivers on Enova's commitment to bringing life-changing technologies to market. "This venture perfectly illustrates Enova's strategy of fostering a collaborative community of medical professionals that discovers new ideas and quickly turns them into innovative healthcare products," he said. "Exos is the direct result of combining P.I.'s tremendous creative and design capabilities with Enova's skill in bringing revolutionary medical technology ideas to life."

Mark Joseph, P.I. president, developer of the OrthoFoam technology, and Exos board member, is excited to be teaming with Enova. "Together we are turning a good idea into a reality in the marketplace. Exos is our common vision to make a serious difference in a field that we believe is long overdue for new technology. Casting has seen little improvement over the past twenty-five years when compared with other medical fields and we intend to raise it to a new level."

Patents are pending on the OrthoFoam technology. Exos bracing, splinting and casting products will be considered Class I medical devices according to FDA regulations. The first product launch is expected in early 2008.

Enova Medical Technologies, a privately held company, is engaged in the development and commercialization of proprietary medical devices and is an experienced provider of product development, manufacturing, and commercialization services for the medical device industry. From Class I to Class III devices, Enova understands the technical challenges of product design, engineering, research and development, the regulatory steps required to successfully commercialize products, and the marketing and sales efforts needed to move inventory off the shelf. For more information, visit

Product Innovations, a privately held company, was founded in 1982 in Aspen, Colo., and has developed a wide variety of products for the lighting, footwear, outdoor, sporting and ski industries. For more information, visit

SOURCE Enova Medical Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Renovar captures $1.2M for product development
2. Cisco Chairman donates $31 million for UW building renovation
3. Medical College receives $377K to study brain disease
4. Barriers will not stop convergence of medical technologies
5. Medical College team creates website for tracking flu
6. Biomedical engineering conference invites manufacturers
7. Visions: Wade offers straight talk on e-medical records
8. Merge unveils updated medical imaging software
9. Medical College receives $1.4M cancer grant
10. Medical technology firm lands $100K federal grant
11. Doyle outlines spending for Medical College, UWM
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample ... the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity ...
(Date:6/23/2016)... BEACH, Calif. , June 23, 2016  Blueprint ... new biological discoveries to the medical community, has closed ... co-founder Matthew Nunez . "We have ... us with the capital we need to meet our ... will essentially provide us the runway to complete validation ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest ... ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials in ...
(Date:6/23/2016)... FRANCISCO , June 22, 2016  Amgen (NASDAQ: ... sponsorship of the QB3@953 life sciences incubator ... human health. The shared laboratory space at QB3@953 was ... overcome a key obstacle for many early stage organizations ... part of the sponsorship, Amgen launched two "Amgen Golden ...
Breaking Biology Technology:
(Date:6/20/2016)... June 20, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring ... involved, it has secured the final acceptance by ... for Managed Access Systems (MAS) installed. Furthermore, Securus ... to be installed by October, 2016. MAS distinguishes ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
Breaking Biology News(10 mins):